ClinicalTrials.gg
Active, not recruitingNCT06749457PEAKUpdated Oct 28, 2026

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

A Phase 1/2 interventional study of AZD7760 and Placebo in Staphylococcus Aureus, sponsored by AstraZeneca. Active, not recruiting at 40 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Prevention

Updated Oct 28, 2026Now Active, not recruitingEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies in Staphylococcal Infections with a site in United States — 6 open to participants now, 11 under way, none of them phase 3. Staphylococcal Infections · United States.

Enrollment
33rd of 92
242 · median 158
Started
2024
with 4 others
Phase 1/2
6 of 125
none open now
Primary completion
2027-03
later than 6 of 10 live
Registered
124th of 125
by date

Among the 125 studies in Staphylococcal Infections with a site in United States, this one is the 33rd largest by enrollment of the 92 interventional ones that give a count, is one of 5 that started in 2024, is one of 6 in phase 1/2, reaches primary completion later than 6 of the 10 other live ones, and was the 124th registered.

Staphylococcal Infections

304 studies on the registry are indexed under Staphylococcal Infections; 35 are open to participants now.

Browse Staphylococcal Infections studies →

Open to participants now

6 of the 125 studies in Staphylococcal Infections with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Staphylococcal Infections studies recruiting now, 16 (73%) set no upper age limit and 4 (18%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Staphylococcal Infections with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).

Read the detailed description

In the Phase I portion of the study, participants will be randomized to receive one of 3 dosages of AZD7760 or placebo as a single intravenous infusion.

Study details include:

  • A 28-day Screening Period.
  • A Dosing Period of 3 days in which a single intravenous infusion will be given on Day 1.
  • A Follow-up Period of 12 months from the time of administration of the study intervention.

In the Phase IIa portion of the study, participants will be randomized to receive either AZD7760 or placebo as 2 intravenous infusions given 3 months apart.

Study details include:

  • A 28-day Screening Period.
  • A Dosing Period in which 2 intravenous infusions will be given 3 months apart (Day 1 and Day 91).
  • A Follow-up Period of 12 months after the last administration of the study intervention on Day 91.
03

Conditions studied

  • Staphylococcus Aureus

Keywords

  • Bloodstream infection
  • End-stage kidney disease
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase I:

  • Participant must be 18 to 55 years of age (inclusive), at the time of signing the .
  • Body weight ≥ 45 kilograms (kg) and ≤ 110 kg and (BMI) within the range ≥ 18.0 to ≤ 30.0 kilograms per square meter (kg/m2) (inclusive) at screening.
  • Healthy participants with no concomitant diseases or medications (except for those specifically permitted by the protocol) according to medical history, physical examination, screening safety laboratory tests, and screening parameters, as per the judgement of the investigator.

Phase IIa:

  • Participant must be ≥ 18 years of age at the time of signing the informed consent.
  • Participants who meet all of the following disease status requirements:

    1. Diagnosed with End-stage kidney disease (ESKD).
    2. Requiring hemodialysis through a tunneled central venous catheter as the primary vascular access for hemodialysis.
    3. Receiving hemodialysis for treatment of ESKD for at least 60 days before randomization.
    4. At least 3 previous dialysis sessions using current dialyzer.
    5. Receiving adequate hemodialysis based on a single-pool Kt/V measurement > 1.2 within the last 30 days.
    6. No new medications have been added to the participant's regimen in the last 2 weeks prior to dosing. 'New medication' is defined as any medication that has not been prescribed or used by the participant previously (including formulation changes). Medication previously prescribed or used by the participant with dose adjustments is allowed and not considered as new medication for the purpose of this study.
    7. Not taking long-term systemic antibiotics with activity against S aureus.

Exclusion criteria

Exclusion Criteria:

Phase I:

  • Known to any component of the study intervention
  • Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of monoclonal antibodies (mAbs).
  • bleeding disorder (eg, factor deficiency, coagulopathy, or disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.
  • (AST) or alanine Aminotransferase (ALT) above 1.5 × (ULN) at screening. Testing may be repeated once at the investigator's discretion.
  • Estimated \< 90 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation at screening.
  • or platelet count below the lower limit of normal at screening. Testing may be repeated once at the investigator's discretion.
  • White blood cell counts outside normal reference ranges unless judged by the investigator to be out of range given the known variation in white blood cell count reference interval by ethnicity. Testing may be repeated once at the investigator's discretion.
  • History of other than treated non-melanoma skin cancers or locally treated cervical cancer in the previous 5 years.
  • Any laboratory value in the screening panel that, in the opinion of the investigator, is clinically significant or might confound analysis of study results. Testing may be repeated once at the investigator's discretion.
  • Any clinically significant abnormalities on 12-lead (ECG) at screening, as judged by the investigator.
  • Acute (time-limited) illness, including fever ≥ 38 °C (100.4 °F), one day prior to or on day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves within the 28-day Screening Period or may be rescreened once.
  • Known or suspected congenital or acquired immunodeficiency, or receipt of therapy, including any course of therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening.
  • Any condition that has the potential to increase clearance of the study intervention (eg, protein loss conditions such as severe enteropathies, or plasmapheresis).
  • Blood drawn in excess of a total of 450 milliliters (mL) (1 unit) for any reason within 2 months prior to screening.
  • Absence of suitable veins for blood sampling and administration of study intervention.
  • Any other condition that would compromise safety of the participants.
  • Any condition that, in the opinion of the investigator, might interfere with evaluation of the study intervention or interpretation of participant safety or study results.

Phase IIa:

  • Known hypersensitivity to any component of the study intervention.
  • History of allergic disease or reactions likely to be exacerbated by any component of the study intervention as listed in dose formulation section.
  • Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of mAbs.
  • Hemoglobin \< 9 g/dL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.
  • Serum albumin of \< 3 g/dL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.
  • Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thrombotic/thromboembolic event (eg, deep vein thrombosis or pulmonary embolism, but excluding vascular access thrombosis) within 90 days prior to randomization.
  • Known S aureus infection within 90 days of study entry.
  • Known acute viral or bacterial infection or symptoms/signs consistent with such an infection within the 21 days prior to infusion or study intervention. Mild intercurrent viral illness with a temperature of 38.1 °C (100.6 °F) or less does not require exclusion, if in the judgement of the investigator this illness will not interfere with the evaluation of the mAb.
  • Participants with malignancy undergoing chemotherapy.
  • Scheduled date for living donor kidney transplant.
  • Plans to switch to peritoneal dialysis within the primary endpoint time period (181 days).
  • Regarding arteriovenous fistula (AVF) or arteriovenous graft (AVG):

    (a) Future AVG or AVG: (i) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG use within 90 days of randomization are not eligible.

(ii) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG placement, but no plans for AVF or AVG use within 90 days of randomization are eligible.

(b) Existing AVG or AVG: (i) Participants with central venous catheters in use for dialysis, but also with an existing AVF or AVG that is not in use and with no future plans for use are eligible.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    Phase I: AZD7760 Dose A

    Participants will receive a single dose of AZD7760 Dose A intravenously on Day 1.

    Drug: AZD7760

  • Experimental
    Phase I: AZD7760 Dose B

    Participants will receive a single dose of AZD7760 Dose B intravenously on Day 1.

    Drug: AZD7760

  • Experimental
    Phase I: AZD7760 Dose C

    Participants will receive a single dose of AZD7760 Dose C intravenously on Day 1.

    Drug: AZD7760

  • Placebo comparator
    Phase I: Placebo

    Participants will receive a single dose of placebo on Day 1.

    Other: Placebo

  • Experimental
    Phase IIa: AZD7760 Dose D and Placebo

    Participants will receive AZD7760 Dose D and placebo on Day 1 on Day 91.

    Drug: AZD7760 · Other: Placebo

  • Experimental
    Phase IIa: AZD7760 Dose E

    Participants will receive AZD7760 Dose E on Day 1 and Day 91.

    Drug: AZD7760

  • Placebo comparator
    Phase IIa: Placebo

    Participants will receive placebo on Day 1 and on Day 91.

    Other: Placebo

Interventions

  • DrugAZD7760

    Participants will receive AZD7760 as a single intravenous infusion.

  • OtherPlacebo

    Participants will be administered placebo through intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Phase I: Occurence of adverse events (AEs)

    To evaluate the safety of AZD7760 administered as a single intravenous (IV) Dose A, B, or C.

    Time frame: Day 1 to Day 181

  2. Phase I: Occurence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)

    To evaluate the safety of AZD7760 administered as a single IV Dose A, B, or C.

    Time frame: Day 1 to Day 361

  3. Phase IIa: Occurrence of AEs, MAAEs, SAEs, and AESIs

    To evaluate the safety of AZD7760 compared with placebo as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E

    Time frame: Day 1 to Day 181

Secondary outcomes

  1. Phase I: Maximum observed plasma (peak) drug concentration (Cmax)

    To characterize the pharmacokinetics (PK) of AZD7760 in serum.

    Time frame: Day 1 to Day 361

  2. Phase I: Time to reach peak or maximum observed concentration following drug administration (tmax)

    To characterize the PK of AZD7760 in serum.

    Time frame: Day 1 to Day 361

  3. Phase I: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz)

    To characterize the PK of AZD7760 in serum.

    Time frame: Day 1 to Day 361

  4. Phase I: Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)

    To characterize the PK of AZD7760 in serum.

    Time frame: Day 1 to Day 361

  5. Phase I: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf)

    To characterize the PK of AZD7760 in serum.

    Time frame: Day 1 to Day 361

  6. Phase I: Apparent volume of distribution at steady state (Vss)

    To characterize the PK of AZD7760 in serum.

    Time frame: Day 1 to Day 361

  7. Phase I: Apparent volume of distribution at the terminal phase (Vz)

    To characterize the PK of AZD7760 in serum.

    Time frame: Day 1 to Day 361

  8. Phase I: Incidence of ADA

    To evaluate ADA responses to AZD7760 in serum.

    Time frame: Day 1 to Day 361

  9. Phase IIa: Cmax

    To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E

    Time frame: Day 1 to Day 181 and Day 1 to Day 451

  10. Phase IIa: tmax

    To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E

    Time frame: Day 1 to Day 181 and Day 1 to Day 451

  11. Phase IIa: t1/2λz

    To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E

    Time frame: Day 1 to Day 181 and Day 1 to Day 451

  12. Phase IIa: AUClast

    To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E

    Time frame: Day 1 to Day 181 and Day 1 to Day 451

  13. Phase IIa: AUCinf

    To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E

    Time frame: Day 1 to Day 181 and Day 1 to Day 451

  14. Phase IIa: Vss

    To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E

    Time frame: Day 1 to Day 181 and Day 1 to Day 451

  15. Phase IIa: Vz

    To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E

    Time frame: Day 1 to Day 181 and Day 1 to Day 451

  16. Phase IIa: Incidence of anti-drug antibodies (ADAs) to AZD7760 in serum

    To evaluate ADA responses to AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E

    Time frame: Day 1 to Day 181 and Day 1 to Day 451

  17. Phase IIa: Occurrence of AEs

    To evaluate the safety to Day 181 of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E

    Time frame: Day 1 to Day 181

  18. Phase IIa: Occurrence of MAAEs, SAEs, and AESIs

    To evaluate the safety to Day 451 of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E

    Time frame: Day 1 to Day 451

07

Study locations

40 sites
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    Chula Vista, California 91910, United States
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Granada Hills, California 91344, United States
  • Research Site
    Los Angeles, California 90027, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Northridge, California 91325, United States
  • Research Site
    Oxnard, California 93036, United States
  • Research Site
    Riverside, California 92503, United States
  • Research Site
    San Dimas, California 91773, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Valencia, California 91355, United States
  • Research Site
    Victorville, California 92392, United States
  • Research Site
    Englewood, Colorado 80110, United States
  • Research Site
    Bradenton, Florida 34209, United States
  • Research Site
    Coral Springs, Florida 33071, United States
  • Research Site
    Hollywood, Florida 33024, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Tampa, Florida 33603, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Chicago, Illinois 60640, United States
  • Research Site
    Chicago, Illinois 60643, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    Baltimore, Maryland 21225, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Pontiac, Michigan 48341, United States
  • Research Site
    Tupelo, Mississippi 38801, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Lincoln, Nebraska 68510, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Jersey City, New Jersey 07305, United States
  • Research Site
    Albuquerque, New Mexico 87109, United States
  • Research Site
    Ridgewood, New York 11385, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Bethlehem, Pennsylvania 18017, United States
  • Research Site
    Beaumont, Texas 77706, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    McAllen, Texas 78503, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2024 (actual). Primary completion is estimated for Mar 2027, 26 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Apr 2027 → Mar 2027 and completion Jan 2028 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Dec 27, 2024
StartActual
Dec 30, 2024
Primary completionEst.
Mar 8, 2027was Apr 2027
CompletionEst.
Dec 13, 2027was Jan 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 6, 2026
Sites
4 sites removed
Show 4 removed
  • Research Site · Chula Vista, United States
  • Research Site · Kinston, United States
  • Research Site · Knoxville, United States
  • Research Site · San Antonio, United States
Oct 6, 2026
Primary completion
Apr 2, 2027→Mar 8, 2027
Oct 6, 2026
Study completion
Jan 7, 2028→Dec 13, 2027
Oct 6, 2026
Enrollment
231 (estimated)→242
Oct 28, 2026
Show all 2 updates
  1. Oct 28, 2026
    Enrollment 244→242
  2. Oct 6, 2026
    Recruiting→Active, not recruiting
    4 sites removed
    Show 4 removed
    • Research Site · Chula Vista, United States
    • Research Site · Kinston, United States
    • Research Site · Knoxville, United States
    • Research Site · San Antonio, United States
    Primary completion Apr 2, 2027→Mar 8, 2027
    Study completion Jan 7, 2028→Dec 13, 2027
    Enrollment 231 (estimated)→244 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06749457
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Dec 27, 2024
Start date
Dec 30, 2024
Primary completion
Mar 8, 2027 (estimated)
Completion
Dec 13, 2027 (estimated)
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion